138 related articles for article (PubMed ID: 37368111)
1. Ethnic diversity in treatment response for colorectal cancer: proof of concept for radiomics-driven enrichment trials.
Dercle L; Yang M; Gönen M; Flynn J; Moskowitz CS; Connors DE; Yang H; Lu L; Reidy-Lagunes D; Fojo T; Karovic S; Zhao B; Schwartz LH; Henick BS
Eur Radiol; 2023 Dec; 33(12):9254-9261. PubMed ID: 37368111
[TBL] [Abstract][Full Text] [Related]
2. An imaging signature to predict outcome in metastatic colorectal cancer using routine computed tomography scans.
Dercle L; Zhao B; Gönen M; Moskowitz CS; Connors DE; Yang H; Lu L; Reidy-Lagunes D; Fojo T; Karovic S; Maitland ML; Oxnard GR; Schwartz LH
Eur J Cancer; 2022 Jan; 161():138-147. PubMed ID: 34916122
[TBL] [Abstract][Full Text] [Related]
3. Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab.
Dohan A; Gallix B; Guiu B; Le Malicot K; Reinhold C; Soyer P; Bennouna J; Ghiringhelli F; Barbier E; Boige V; Taieb J; Bouché O; François E; Phelip JM; Borel C; Faroux R; Seitz JF; Jacquot S; Ben Abdelghani M; Khemissa-Akouz F; Genet D; Jouve JL; Rinaldi Y; Desseigne F; Texereau P; Suc E; Lepage C; Aparicio T; Hoeffel C;
Gut; 2020 Mar; 69(3):531-539. PubMed ID: 31101691
[TBL] [Abstract][Full Text] [Related]
4. Radiomics analysis of pre-treatment [
van Helden EJ; Vacher YJL; van Wieringen WN; van Velden FHP; Verheul HMW; Hoekstra OS; Boellaard R; Menke-van der Houven van Oordt CW
Eur J Nucl Med Mol Imaging; 2018 Dec; 45(13):2307-2317. PubMed ID: 30094460
[TBL] [Abstract][Full Text] [Related]
5. The relevance of CT-based geometric and radiomics analysis of whole liver tumor burden to predict survival of patients with metastatic colorectal cancer.
Mühlberg A; Holch JW; Heinemann V; Huber T; Moltz J; Maurus S; Jäger N; Liu L; Froelich MF; Katzmann A; Gresser E; Taubmann O; Sühling M; Nörenberg D
Eur Radiol; 2021 Feb; 31(2):834-846. PubMed ID: 32851450
[TBL] [Abstract][Full Text] [Related]
6. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
[TBL] [Abstract][Full Text] [Related]
7. Computed Tomography-Based Radiomic Features Could Potentially Predict Microsatellite Instability Status in Stage II Colorectal Cancer: A Preliminary Study.
Fan S; Li X; Cui X; Zheng L; Ren X; Ma W; Ye Z
Acad Radiol; 2019 Dec; 26(12):1633-1640. PubMed ID: 30929999
[TBL] [Abstract][Full Text] [Related]
8. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
9. Can CT-based radiomics signature predict KRAS/NRAS/BRAF mutations in colorectal cancer?
Yang L; Dong D; Fang M; Zhu Y; Zang Y; Liu Z; Zhang H; Ying J; Zhao X; Tian J
Eur Radiol; 2018 May; 28(5):2058-2067. PubMed ID: 29335867
[TBL] [Abstract][Full Text] [Related]
10. CT-Based Radiomics Analysis Before Thermal Ablation to Predict Local Tumor Progression for Colorectal Liver Metastases.
Taghavi M; Staal F; Gomez Munoz F; Imani F; Meek DB; Simões R; Klompenhouwer LG; van der Heide UA; Beets-Tan RGH; Maas M
Cardiovasc Intervent Radiol; 2021 Jun; 44(6):913-920. PubMed ID: 33506278
[TBL] [Abstract][Full Text] [Related]
11. Identification of Non-Small Cell Lung Cancer Sensitive to Systemic Cancer Therapies Using Radiomics.
Dercle L; Fronheiser M; Lu L; Du S; Hayes W; Leung DK; Roy A; Wilkerson J; Guo P; Fojo AT; Schwartz LH; Zhao B
Clin Cancer Res; 2020 May; 26(9):2151-2162. PubMed ID: 32198149
[TBL] [Abstract][Full Text] [Related]
12. Radiomics Response Signature for Identification of Metastatic Colorectal Cancer Sensitive to Therapies Targeting EGFR Pathway.
Dercle L; Lu L; Schwartz LH; Qian M; Tejpar S; Eggleton P; Zhao B; Piessevaux H
J Natl Cancer Inst; 2020 Sep; 112(9):902-912. PubMed ID: 32016387
[TBL] [Abstract][Full Text] [Related]
13. Computed Tomography-based Radiomics Nomogram for the Preoperative Prediction of Tumor Deposits and Clinical Outcomes in Colon Cancer: a Multicenter Study.
Li M; Xu G; Chen Q; Xue T; Peng H; Wang Y; Shi H; Duan S; Feng F
Acad Radiol; 2023 Aug; 30(8):1572-1583. PubMed ID: 36566155
[TBL] [Abstract][Full Text] [Related]
14. Predictive and prognostic value of CT based radiomics signature in locally advanced head and neck cancers patients treated with concurrent chemoradiotherapy or bioradiotherapy and its added value to Human Papillomavirus status.
Ou D; Blanchard P; Rosellini S; Levy A; Nguyen F; Leijenaar RTH; Garberis I; Gorphe P; Bidault F; Ferté C; Robert C; Casiraghi O; Scoazec JY; Lambin P; Temam S; Deutsch E; Tao Y
Oral Oncol; 2017 Aug; 71():150-155. PubMed ID: 28688683
[TBL] [Abstract][Full Text] [Related]
15. Tumor-infiltrating lymphocyte enrichment predicted by CT radiomics analysis is associated with clinical outcomes of non-small cell lung cancer patients receiving immune checkpoint inhibitors.
Park C; Jeong DY; Choi Y; Oh YJ; Kim J; Ryu J; Paeng K; Lee SH; Ock CY; Lee HY
Front Immunol; 2022; 13():1038089. PubMed ID: 36660547
[TBL] [Abstract][Full Text] [Related]
16. CT-based radiomics nomogram for prediction of survival after transarterial chemoembolization with drug-eluting beads in patients with hepatocellular carcinoma and portal vein tumor thrombus.
Cheng S; Hu G; Jin Z; Wang Z; Xue H
Eur Radiol; 2023 Dec; 33(12):8715-8726. PubMed ID: 37436507
[TBL] [Abstract][Full Text] [Related]
17. CT-based radiomics signatures can predict the tumor response of non-small cell lung cancer patients treated with first-line chemotherapy and targeted therapy.
Yang F; Zhang J; Zhou L; Xia W; Zhang R; Wei H; Feng J; Zhao X; Jian J; Gao X; Yuan S
Eur Radiol; 2022 Mar; 32(3):1538-1547. PubMed ID: 34564744
[TBL] [Abstract][Full Text] [Related]
18. Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(24):1-48. PubMed ID: 23074402
[TBL] [Abstract][Full Text] [Related]
19. A CT-based Radiomics Signature Is Associated with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors.
Ligero M; Garcia-Ruiz A; Viaplana C; Villacampa G; Raciti MV; Landa J; Matos I; Martin-Liberal J; Ochoa-de-Olza M; Hierro C; Mateo J; Gonzalez M; Morales-Barrera R; Suarez C; Rodon J; Elez E; Braña I; Muñoz-Couselo E; Oaknin A; Fasani R; Nuciforo P; Gil D; Rubio-Perez C; Seoane J; Felip E; Escobar M; Tabernero J; Carles J; Dienstmann R; Garralda E; Perez-Lopez R
Radiology; 2021 Apr; 299(1):109-119. PubMed ID: 33497314
[TBL] [Abstract][Full Text] [Related]
20. Dual-region radiomics signature: Integrating primary tumor and lymph node computed tomography features improves survival prediction in esophageal squamous cell cancer.
Lu N; Zhang WJ; Dong L; Chen JY; Zhu YL; Zhang SH; Fu JH; Yin SH; Li ZC; Xie CM
Comput Methods Programs Biomed; 2021 Sep; 208():106287. PubMed ID: 34311416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
